Great Lakes NeuroTechnologies Inc.

What Great Lakes NeuroTechnologies Inc. does

Great Lakes NeuroTechnologies Inc. (GLNT) is a Cleveland/Independence, Ohio-based biomedical technology company founded in 2006 that develops wearable, sensor-based systems for the objective assessment of movement disorders, principally Parkinson's disease and essential tremor. Its flagship Kinesia family — Kinesia ONE, Kinesia 360, and the prescription medical app KinesiaU — uses proprietary, clinically validated machine learning algorithms applied to accelerometer and gyroscope data (including from consumer Apple Watch and Android smartwatches) to quantify tremor, bradykinesia, and dyskinesia severity for clinicians and patients. The company is also developing DBS-Expert Pro, an automated deep brain stimulation programming system funded under a $2.1M NIH SBIR Phase II grant, alongside a secondary BioRadio product line that supplies wireless physiological data acquisition hardware and supporting software (BioCapture, Lab Course, SDK) to research and education markets.

GLNT operates a multi-segment business model spanning medical device hardware sales (BioRadio, Kinesia ONE/360), prescription subscription software (KinesiaU via Apple App Store and Google Play), clinical research services sold to pharmaceutical and medical device sponsors, and research/education software licenses. Go-to-market is sales-led and direct for enterprise pharma and clinical trial customers, supplemented by prescription app-store distribution for patients and a UK channel partnership with Henry Schein Medical that follows the 2023 NICE DG51 recommendation for KinesiaU and Kinesia 360 in remote Parkinson's monitoring. The technology is FDA-cleared, UKCA-marked, and protected by 33 US and international patents, giving the company a defensible regulatory and IP position in a niche but high-clinical-value category within digital neurology.

Name

Great Lakes NeuroTechnologies Inc.

Legal name

Great Lakes NeuroTechnologies Inc.

Website

https://glneurotech.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Great Lakes NeuroTechnologies develops FDA-cleared, wearable sensor-based Kinesia systems that use proprietary ML algorithms to objectively assess Parkinson's disease and essential tremor, serving clinicians, pharma clinical trials, academic researchers, and patients via prescription medical apps.

Ownership category

akta.pro rank

Product category

Medical Devices for Movement Disorder Monitoring

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Scientific Research and Development Services (5417)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

akta.pro secondary industries

Movement Disorders (Parkinson’s, Tremor, Dystonia) (HLAKAIAC), Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB), Neurology RPM (epilepsy, Parkinson’s, MS monitoring) (HLALAFAJ), Neurology Telemedicine Platforms (HLALAGAC)

Keywords

• Wearable medical devices
• Movement disorder monitoring
• Clinical research technology
• Physiological data acquisition
• Deep brain stimulation

Headquarters

HQ city

Cleveland

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Hardware Sales: Sale of BioRadio wireless physiological monitoring devices for research and education purposes. The BioRadio is sold with various software options including BioCapture and Lab Course.
2. Prescription Medical Software/Subscriptions: KinesiaU motor assessment system available by prescription through app stores. Kinesia ONE and Kinesia 360 systems sold to healthcare providers and clinical trials.
3. Clinical Research Services: Providing Kinesia technology to pharmaceutical companies and medical device companies for clinical trials, positioning the technology as the gold-standard for objective sensor measurement.
4. Research and Education Software: BioCapture research software and BioRadio Lab Course educational curriculum sold or licensed to research institutions and educational facilities.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Great Lakes NeuroTechnologies develops and sells FDA-cleared wearable biomedical technologies for the objective assessment and remote monitoring of movement disorders, primarily Parkinson's disease and essential tremor. Its Kinesia product family (Kinesia ONE, Kinesia 360, KinesiaU) uses motion sensors and proprietary machine learning algorithms to quantify tremor, slowness, and dyskinesia for clinicians, clinical trials, and patients. The company also offers the BioRadio wireless physiological monitoring platform for research and education markets, and is developing the DBS-Expert Pro system for automated deep brain stimulation programming.

Product overview

Great Lakes NeuroTechnologies offers a comprehensive portfolio of bioinstrumentation products centered on the Kinesia and BioRadio platforms. The Kinesia family (Kinesia ONE, Kinesia 360, KinesiaU) provides wearable, objective, automated assessment of movement disorders such as Parkinson's disease and essential tremor using clinically validated machine learning algorithms based on motion sensor data. Kinesia ONE and Kinesia 360 serve clinical and research markets with varying sensitivity levels, while KinesiaU is a prescription medical app leveraging consumer smartwatches (Apple Watch, Android) for patient self-monitoring with clinician portal access. The BioRadio platform serves research and education markets with wireless physiological data acquisition hardware and supporting software (BioCapture, BioRadio Lab Course, SDK). The company is developing DBS-Expert Pro for automated deep brain stimulation programming. Products feature wireless, remote, and web-based integrations with major markets in movement disorders, telemedicine, and physiological monitoring for research and education.

Differentiator

Problem solved

Functional benefit

Brands

• Kinesia: Wearable, objective, and automated assessment technology for movement disorders such as Parkinson's disease and essential tremor. Includes Kinesia ONE, Kinesia 360, and KinesiaU product lines.
• Kinesia ONE
• Kinesia 360
• KinesiaU
• BioRadio

Products and services

• Kinesia ONE A motor assessment system for objective monitoring of movement disorders such as Parkinson's disease and essential tremor. Clinically validated technology adopted as the gold-standard for objective sensor measurement in healthcare and clinical research settings.
• Kinesia 360 A motor assessment system primarily used in clinical trials that includes an additional leg sensor for increased sensitivity. Monitors tremor, slowness, and dyskinesia with patients viewing symptoms on smartphones and clinicians accessing data remotely in real-time through a web portal.
• KinesiaU A validated, FDA-cleared prescription medical app for individuals to measure Parkinson's disease and essential tremor symptoms using an iPhone or Android smartphone and smartwatch. Tracks tremors, slowness, and dyskinesia as well as therapies and activities. Available by prescription in the US and UK markets.
• BioRadio A compact wireless physiological data acquisition system for research and education. Records a variety of physiological signals including those from piezo-electric, resistive, infrared, conductive, and thermoelectric sensors. Features 8GB internal storage, rechargeable battery, and multi-channel wireless data acquisition.
• BioRadio Lab Course A biomedical teaching system designed to expose students to human physiological signal acquisition, data analysis, signal processing, biomedical engineering, and clinical concepts. Curriculum aligned with ABET standards for meeting program learning objectives. Sold to universities and educational institutions.

Quantifiable outcome

• Clinician five times more likely to recommend a patient for advanced therapy when given access to Kinesia objective remote monitoring reports
• +2 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability5 records

Feature7 records

Partnerships

One partnership is on record.

• Henry Schein Medical UKcoreChannel Partner/ Reseller/ Distributor · 24 April 2025Distribution agreement where Henry Schein Medical UK distributes GLNT's Kinesia motor assessment system line of products including Kinesia ONE, Kinesia 360, and KinesiaU in the UK. This partnership follows NICE's recommendation of KinesiaU and Kinesia 360 for remote monitoring of Parkinson's disease and significantly expands access to the UK's 150,000+ Parkinson's patients.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Rune Labs: StrivePD developer providing wearable, objective Parkinson's disease symptom monitoring using Apple Watch and machine learning, with pharma clinical trial endpoint services — directly competes with KinesiaU and Kinesia 360 across both patient app and pharma clinical trial use cases.
• Empatica: Developer of FDA-cleared wearable biosensors (EpiMonitor) and digital biomarkers for neurological conditions including epilepsy and Parkinson's disease; competes in the same wearable, AI-driven neurological monitoring category as the Kinesia product line.
• Cala Health: Developer of FDA-cleared wearable neuromodulation therapy (Cala TAPS) for essential tremor and Parkinson's disease; serves the same essential tremor and Parkinson's patient population as Great Lakes NeuroTechnologies with a wearable, prescription-based device model.

Broad incumbents

• Medtronic: Global leader in deep brain stimulation (DBS) systems for Parkinson's disease and a partner/incumbent in the DBS ecosystem where Great Lakes NeuroTechnologies' DBS-Expert Pro automated programming tool aims to integrate; competes implicitly via Percept PC neurostimulator with embedded sensing capabilities.
• Abbott: Major DBS manufacturer (Infinity DBS) for movement disorders including Parkinson's disease; relevant incumbent because the company's DBS-Expert Pro must integrate with commercial DBS platforms, positioning Abbott as both potential integration partner and competitor with proprietary programming tools.
• Boston Scientific: Boston Scientific's Vercise DBS system competes in the same Parkinson's DBS market where Great Lakes NeuroTechnologies is developing automated programming; relevant as another incumbent DBS manufacturer that DBS-Expert Pro would need to integrate with or compete against.
• iRhythm Technologies: Public wearable cardiac monitoring company (Zio) using patch-based biosensors and AI algorithms to deliver continuous physiological monitoring; relevant comparable for the wearable + AI-driven remote patient monitoring business model Great Lakes NeuroTechnologies is pursuing in neurology.

Emerging players

• MC10: Developer of flexible wearable bioelectronic sensors for clinical research and patient monitoring, including motion and physiological signal capture; comparable to Great Lakes NeuroTechnologies' BioRadio platform in the wearable biosignal acquisition category.
• Biofourmis: AI-powered remote patient monitoring and digital therapeutics platform covering chronic conditions; comparable to Great Lakes NeuroTechnologies' KinesiaU prescription RPM approach but with broader therapeutic scope and stronger commercial scaling.

Regional players

• NeuroPace: Developer of the RNS System, an FDA-cleared closed-loop neurostimulation device for epilepsy with embedded EEG monitoring; relevant adjacent peer in the neurological wearable/implantable monitoring category, though primarily US-focused and targeting epilepsy rather than movement disorders.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/great-lakes-neurotech

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Great Lakes NeuroTechnologies Inc.